CDSCO Cancels Registration Certificate of G3 Medical Systems for Import of Allergan Cosmetics

Published On 2025-09-19 05:30 GMT | Update On 2025-09-19 05:30 GMT

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has confirmed the cancellation of Registration Certificate (RC) No. RC/COS-002850, previously issued to G3 Medical Systems Pvt. Ltd., Chennai, for the import of cosmetics manufactured by Allergan Sales LLC, USA.

According to CDSCO, the company had applied through the SUGAM portal (application no. COS/PostAppr/2025/38350 dated May 21, 2025) seeking voluntary surrender of the registration. Acting on the request, the regulatory authority has officially cancelled the RC with immediate effect.

Also Read: Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO

The notice read,

"Please refer to your application number COS/PostAppr/2025/38350 dated 2'1- May-2025 received on SUGAM Portal for surrender of subject RC by you. As per your request, Registration Certificate No. RC/COS-002850 dated 14-Dec-2021 valid up to 13-Dec-2026 issued to you for the purpose of import of cosmetics manufactured by M/s Allergan Sales LLC, 2525 Dupont Drive,lrvine,CA 92612 - (United States) shall be treated as cancelled with immediate effect."

The certificate, originally granted on December 14, 2021, was valid until December 13, 2026. With this cancellation, G3 Medical Systems will no longer be authorized to import the said cosmetics into India.

As part of the regulatory process, CDSCO has also circulated the order to all Zonal, Sub-Zonal, and Port Offices to ensure compliance and prevent import of the products under the surrendered registration.

Also Read: Govt Allows Stickering, Orders New MRPs Post GST Reduction, AiMeD Welcomes Directive

To view the official notice, click the link below:

https://medicaldialogues.in/pdf_upload/surrender-g3-medical-system-on-15092025-301310.pdf

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Cancels Registration Certificate of G3 Medical Systems for Import of Allergan Cosmetics

Similar News

AstraZeneca Gets SEC Nod for New Trastuzumab Deruxtecan Indication in HER2-Positive Solid Tumors

No Entry Without Notice: CDSCO Directs All Drug Shipments Through Notified Ports via ICEGATE

Lupin Launches Strategic Partnership to Expand PrecisionSphere Long-Acting Injectable Platform

Chemist Loses Rs 1.01 Crore in Social Media Investment Scam

Bhopal Pharmacy Owner Gets 3-Year Jail Sentence for Running Store Without Pharmacist

Rs 233 Crore in 6 Months: Mounjaro Becomes India's Second-Biggest Drug by Sales

Maharashtra FDA Launches Special Drive to Inspect Liquid Oral Formulations

Rubicon Research Raises Rs 619 Crore Pre-IPO, Eyes October 16 Listing